The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Giraffe restaurants
Advised Tesco plc, a listed FTSE 100 retailer, on its sale of the Giraffe casual dining restaurant chain to the Boparan Private Office, the private investment vehicle of the British businessman Ranjit Boparan
Asia and US rights to Physiogel
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd
Pension Trustees of Howden Joinery Group plc
Advised the Pension Trustees of Howden Joinery Group plc in negotiating a revised schedule of deficit reduction payments, and with regards to their security position relative to the Company’s lenders
Rights to Three Skin Care Brands in Mexico
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the Mexico rights to Hinds, Capent and Eclipsol to Mexico-based Grisi Hnos
Lion’s Australian Premium Wine Business – Fine Wine Partners
Advised Lion, a leading Australasian food and beverage company wholly owned by Japanese conglomerate Kirin, on the sale of its Australian wine business Fine Wine Partners to Accolade Wines, a portfolio company of CHAMP Private Equity
Tesco PLC's Chinese retail operations
Advised Tesco PLC on the formation of a joint venture with China Resources Enterprise, a Hong Kong listed, Chinese retailer, to create the leading multi-format retailer in China
Portfolio of GlaxoSmithKline plc consumer and OTC brands
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
Pfizer Inc. Consumer Health Business
Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture
Eisai Distribution Co., Ltd.
Advising Eisai, a Japanese pharmaceutical company, on the sale of Eisai Distribution, a 100% shares holding logistic subsidiary, to Yasuda Logistics Corporation, a Japanese logistic company conducting total logistic services such as Warehousing, Transportation, delivery and forwarding, and Port transportation business, etc.
Fresh & Easy (owned by Tesco plc)
Advised Tesco plc, a listed FTSE 100 retailer, on the sale of a substantive part of Fresh & Easy’s operating business to YFE Holdings, Inc, an affiliate of The Yucaipa Companies, LLC
Yakult Honsha
Advised Danone, a world leading food company, on its business and capital alliance with Yakult Honsha, the largest probiotic dairy product manufacturer in Japan
The Laundress Inc.
Advised The Laundress Inc., a laundry and home cleaning products brand, on its sale to Unilever, a British-Dutch consumer goods company
Allied Healthcare
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
Kyowa Kirin International’s established medicines business
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
Lazada Group GmbH
Advised Tesco plc, a listed FTSE 100 retailer, on its acquisition of a significant minority shareholding in Lazada, the leading online general merchandise retailer in South East Asia
Rights to General, Right Guard and Dry Idea brands
Advised Henkel on its brand divestment program (including the sale of the General, Right Guard and Dry Idea brands)
Four Pillars Gin
Advised Lion, an Australian subsidiary of Kirin, on its acquisition of a strategic stake in Four Pillars Gin, Australia’s leading craft gin distillery
Clinigen Ltd’s Lamda Laboratories
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
K-Y brand
Advised Reckitt Benckiser, a leading consumer goods manufacturer, on the acquisition of the global rights to the K-Y brand, a leader in intimate lubricants
Mãe Terra Produtos Naturais Ltda.
Advised Mãe Terra Produtos Naturais Ltda., Brazil’s leading Natural & Organic food products company, on its sale to The Unilever Group
Bell's Brewery
Advised Lion, one of Australasia’s leading beverage companies and a wholly owned subsidiary of Japanese conglomerate Kirin Holdings, on the acquisition of Bell’s Brewery, a leading US independent craft brewery
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
Interamericana Trading Corporation and Simpson Motors
Advising Inchcape plc, the leading independent global automotive distributor, on the acquisition of Interamericana Trading Corporation (“ITC”), a leading independent automotive distributor in the Caribbean region, and Simpson Motors, the leading automotive retailer in Barbados, from the Simpson Group
Clinigen Ltd’s portfolio of Established Medicines
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners